As a wholly-owned venture capital fund within the AstraZeneca Group, MedImmune Ventures (MV) invests in private companies which develop small and large molecules, vaccines, pharmaceutical technologies and platforms. We also seek investments in medical devices, diagnostics, imaging and healthcare IT which pertain to the discovery, development and commercialization of pharmaceutical products.
Our therapeutic scope is broad, as is our geographic interest. While MV had initially focused on North America, we will currently consider companies anywhere in the world where we have strong local relationships.
Stage-wise, MV invests in companies with early to late stage products and technologies, in early (e.g. seed) to late (e.g. mezzanine) rounds of financing.
With $300M under management in an evergreen fund, MV has invested in over 30 companies since 2002.
To learn more about each company, visit our Portfolio section.